FLAGYL 500 MG
METRONIDAZOLE : 500 MG · DIN 01926853 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED PRE MARKET
What is FLAGYL?
FLAGYL 500 MG contains METRONIDAZOLE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 01926853, held by SANOFI-AVENTIS CANADA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 15-May-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FLAGYL used for?
Trichomonal infections, hepatic and intestinal amebiasis, giardiasis, bacterial vaginosis, and serious anaerobic intra-abdominal, brain, or lung infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01926853 |
|---|---|
| Brand name | FLAGYL |
| Generic / active ingredient | METRONIDAZOLE : 500 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 500 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | P01AB01 METRONIDAZOLE |
| AHFS class | 08:30.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 15-May-2024 |
| Original market date | 1979-12-31 00:00:00 |
How is it administered?
Trichomoniasis: 2g single dose or 250mg BID for 10 days. Amebiasis: 500-750mg TID for 5-7 days. Bacterial Vaginosis: 500mg BID for 7 days. Anaerobic infections: 500mg every 8 hours.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 and 30°C.
How is it supplied?
Bottles of 100 capsules.
Contraindications
Hypersensitivity to metronidazole or nitroimidazole derivatives; active neurological disorders; history of blood dyscrasia, hypothyroidism, or hypoadrenalism.
Warnings and precautions
Carcinogenic in mice/rats. Risk of severe neurological disturbances (seizures, neuropathy). Severe hepatotoxicity risk in Cockayne syndrome. Avoid alcohol during and 1 day after therapy.
Is METRONIDAZOLE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by PFIZER CANADA ULC, last seen 19 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code P01AB01 METRONIDAZOLE. 7 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-METRONIDAZOLE | 500 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02248562 |
| APO-METRONIDAZOLE TABLETS | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 00545066 |
| AURO-METRONIDAZOLE | 500 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02470284 |
| M-METRONIDAZOLE | 500 MG | CAPSULE | MANTRA PHARMA INC | MARKETED | DIN 02519755 |
| METRONIDAZOLE | 500 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02518767 |
| METRONIDAZOLE | 500 MG | CAPSULE | SANIS HEALTH INC | MARKETED | DIN 02534592 |
| MINT-METRONIDAZOLE | 250 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02535807 |
| APO-METRONIDAZOLE | 250 MG | TABLET | APOTEX INC | CANCELLED PRE MARKET | DIN 02406470 |
| APO-METRONIDAZOLE | 500 MG | CAPSULE | APOTEX INC | CANCELLED PRE MARKET | DIN 02406489 |
| MAR-METRONIDAZOLE | 500 MG | CAPSULE | MARCAN PHARMACEUTICALS INC | APPROVED | DIN 02491370 |
Who else supplies METRONIDAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METRONIDAZOLE appears in 2910 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.